...
search icon
rntx-img

Rein Therapeutics Inc, Common Stock

RNTX

NAQ

$1.67

-$0.04

(-2.34%)

1D

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$40.91M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
744.00
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.23
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.35 L
$4.4 H
$1.67

About Rein Therapeutics Inc, Common Stock

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. Rein Therapeutics Inc. was incorporated in 2001 and is headquartered in Austin, Texas. more

Returns

Data is not properly formatted.

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses20.50M26.61K27.65K16.28K65.11K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.13,"profit":true},{"date":"2022-12-31","value":0.13,"profit":true},{"date":"2023-12-31","value":0.08,"profit":true},{"date":"2024-12-31","value":0.32,"profit":true}]
Operating Income(20.50M)(26.61K)(27.65K)(16.28K)(65.11M)[{"date":"2020-12-31","value":-2049600000,"profit":false},{"date":"2021-12-31","value":-2660500,"profit":false},{"date":"2022-12-31","value":-2764700,"profit":false},{"date":"2023-12-31","value":-1627600,"profit":false},{"date":"2024-12-31","value":-6511200000,"profit":false}]
Total Non-Operating Income/Expense--300.32K400.54K1.20M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":25.03,"profit":true},{"date":"2023-12-31","value":33.38,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(21.20M)(26.16K)(27.33K)(15.73K)(64.31M)[{"date":"2020-12-31","value":-2119600000,"profit":false},{"date":"2021-12-31","value":-2616400,"profit":false},{"date":"2022-12-31","value":-2732900,"profit":false},{"date":"2023-12-31","value":-1573200,"profit":false},{"date":"2024-12-31","value":-6431200000,"profit":false}]
Income Taxes----(1.54M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-154400000,"profit":false}]
Income After Taxes----(62.77M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-6276800000,"profit":false}]
Income From Continuous Operations(21.20M)(26.16M)(27.33M)(15.68M)(62.77M)[{"date":"2020-12-31","value":-2119600000,"profit":false},{"date":"2021-12-31","value":-2616400000,"profit":false},{"date":"2022-12-31","value":-2732900000,"profit":false},{"date":"2023-12-31","value":-1567600000,"profit":false},{"date":"2024-12-31","value":-6276800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(21.16M)(26.16K)(27.33K)(15.73K)(62.88M)[{"date":"2020-12-31","value":-2115700000,"profit":false},{"date":"2021-12-31","value":-2616400,"profit":false},{"date":"2022-12-31","value":-2732900,"profit":false},{"date":"2023-12-31","value":-1573200,"profit":false},{"date":"2024-12-31","value":-6288300000,"profit":false}]
EPS (Diluted)(82.33)(5.91)-(8.41)-[{"date":"2020-12-31","value":-8232.86,"profit":false},{"date":"2021-12-31","value":-591.22,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-840.81,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RNTX
Cash Ratio 2.24
Current Ratio 2.38

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RNTX
ROA (LTM) -31.63%
ROE (LTM) -54.95%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RNTX
Debt Ratio Lower is generally better. Negative is bad. 0.85
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.87

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RNTX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.05
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Rein Therapeutics Inc share price today?

Rein Therapeutics Inc (RNTX) share price today is $1.67

Can Indians buy Rein Therapeutics Inc shares?

Yes, Indians can buy shares of Rein Therapeutics Inc (RNTX) on Vested. To buy Rein Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RNTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Rein Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Rein Therapeutics Inc (RNTX) via the Vested app. You can start investing in Rein Therapeutics Inc (RNTX) with a minimum investment of $1.

How to invest in Rein Therapeutics Inc shares from India?

You can invest in shares of Rein Therapeutics Inc (RNTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in RNTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Rein Therapeutics Inc shares
What is Rein Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Rein Therapeutics Inc (RNTX) is $4.4. The 52-week low price of Rein Therapeutics Inc (RNTX) is $1.35.

What is Rein Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Rein Therapeutics Inc (RNTX) is 1.05

What is the Market Cap of Rein Therapeutics Inc?

The market capitalization of Rein Therapeutics Inc (RNTX) is $40.91M

What is Rein Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Rein Therapeutics Inc is RNTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top